CardioDx abandons IPO plans; AltheaDx eyes $69M IPO; Assurex Health ropes in $30M for neuropsychiatric pharmacogenomics products;

> CardioDx nixed its plans for an IPO, citing unfavorable market conditions. More

> Molecular diagnostics outfit AltheaDx filed plans for a $69 million initial public offering. Story (reg. req.)

> Mental health pharmacogenomics company Assurex Health raked in $30 million to support development of its GeneSight neuropsychiatric products. Story

> Exact Sciences' ($EXAS) shares bounced back on Monday after the Centers for Medicare and Medicaid Services said that it made an error in the 2015 clinical lab fee schedule for the company's Cologuard test. More (reg. req.)

> VolitionRx is launching a clinical study at the University of Bonn in Germany to evaluate its lung cancer diagnostic platform. More

> CardioDx closed a $35 million financing round to support development of its genomic tests for coronary artery disease. More

And Finally… Proove Biosciences inked an exclusive licensing agreement with the University of North Carolina at Chapel Hill's School of Dentistry to incorporate its research on the genetics of pain perception into its diagnostic tests. More (reg. req.)

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.